{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:07:24Z","timestamp":1793984844736,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","award":["Beca Grupos Emergentes 2024"],"award-info":[{"award-number":["Beca Grupos Emergentes 2024"]}],"id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015766","name":"Danone Nutricia Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015766","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To develop and internally validate the PANTHEIA-SIRI prognostic model, which integrates log-transformed systemic inflammation response index (SIRI) with clinical predictors, to estimate overall survival (OS) in metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from the multicenter PANTHEIA-SEOM registry. OS was defined from chemotherapy start. The model was fitted as a Weibull accelerated failure time model in the survival-analysis population with multiple imputation. Predictors were log-transformed baseline SIRI, modeled with restricted cubic splines, ECOG, tumor burden, chemotherapy regimen, and anorexia-cachexia syndrome. Internal validation used a separate, non-overlapping cohort from the same registry; the centers contributing to each cohort are listed in a supplementary annex. TRIPOD was followed. Discrimination was assessed with Harrell\u00b4s C-index and calibration with IPCW Brier scores and IPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The derivation cohort comprised 672 patients with SIRI data (593 analyzed for survival) across 22 Spanish hospitals (2015\u20132025); 80.1% had died after a median OS of 9.9 months. The imputation-pooled derivation C-index was 0.654 (95% CI, 0.627\u20130.681); optimism-corrected, 0.629. Internal validation used 62 separate patients from the same registry; 96.8% had died after a median OS of 9.2 months. The validation C-index was 0.603 (95% CI, 0.518\u20130.687). Calibration was adequate at 6 and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The PANTHEIA-SIRI model provides individualized OS estimates in mPDAC with routine clinical predictors. Its open-access calculator (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/pantheia-siri.shinyapps.io\/calc\/\" ext-link-type=\"uri\">https:\/\/pantheia-siri.shinyapps.io\/calc\/<\/jats:ext-link>\n                      ) may support prognostic communication, treatment-intensity selection, and supportive-care planning. Routine clinical implementation will require further validation in larger, fully independent cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04554-8","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:01:04Z","timestamp":1788415264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHEIA-SEOM cohort"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0141-1306","authenticated-orcid":false,"given":"Vilma","family":"Pacheco-Barcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9668-3983","authenticated-orcid":false,"given":"Axel","family":"Mari\u00f1o-Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7714-5912","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"Vicente Conesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-829X","authenticated-orcid":false,"given":"Mar\u00eda","family":"de Toro Carmena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-188X","authenticated-orcid":false,"given":"Paula","family":"Cerd\u00e0 Serd\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3594-1084","authenticated-orcid":false,"given":"Carmen","family":"Guillen-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Benavente Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3426-7515","authenticated-orcid":false,"given":"Raquel","family":"Hern\u00e1ndez San Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"\u00c1ngela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0584-1242","authenticated-orcid":false,"given":"Javier","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2878-2193","authenticated-orcid":false,"given":"Maria Luisa","family":"Soriano Tabares de Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-4476","authenticated-orcid":false,"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4958-4142","authenticated-orcid":false,"given":"Elena","family":"Brozos-Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7290-3805","authenticated-orcid":false,"given":"Ana","family":"L\u00f3pez-Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-3472","authenticated-orcid":false,"given":"Jorge","family":"Adeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7861-0536","authenticated-orcid":false,"given":"Ismael","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8370-6053","authenticated-orcid":false,"given":"Sandra","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8859-5881","authenticated-orcid":false,"given":"Javier","family":"Soto-Alsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1455-0788","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"4","key":"4554_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021;4(4):e214708.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"4554_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"4554_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"8","key":"4554_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.hpb.2022.01.011","volume":"24","author":"LJ Ioannou","year":"2022","unstructured":"Ioannou LJ, Maharaj AD, Zalcberg JR, Loughnan JT, Croagh DG, Pilgrim CH, et al. Prognostic models to predict survival in patients with pancreatic cancer: a systematic review. HPB (Oxford). 2022;24(8):1201\u201316.","journal-title":"HPB (Oxford)"},{"issue":"6","key":"4554_CR5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/MPA.0000000000001563","volume":"49","author":"D Goldstein","year":"2020","unstructured":"Goldstein D, Von Hoff DD, Chiorean EG, Reni M, Tabernero J, Ramanathan RK, et al. Nomogram for estimating overall survival in patients with metastatic pancreatic cancer. Pancreas. 2020;49(6):744\u201350.","journal-title":"Pancreas"},{"issue":"1","key":"4554_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"11","key":"4554_CR7","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503.","journal-title":"Lancet Oncol"},{"issue":"14","key":"4554_CR8","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/cncr.30057","volume":"122","author":"Q Qi","year":"2016","unstructured":"Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158\u201367.","journal-title":"Cancer"},{"issue":"2","key":"4554_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4251\/wjgo.v16.i2.386","volume":"16","author":"V Pacheco-Barcia","year":"2024","unstructured":"Pacheco-Barcia V, Custodio-Cabello S, Carrasco-Valero F, Palka-Kotlowska M, Mari\u00f1o-Mendez A, Carmona-Bayonas A, et al. Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial. World J Gastrointest Oncol. 2024;16(2):386\u201397.","journal-title":"World J Gastrointest Oncol"},{"key":"4554_CR10","doi-asserted-by":"crossref","unstructured":"Carmona-Bayonas A, Mari\u00f1o M\u00e9ndez A, Vicente Conesa MA, Jimenez-Fonseca P, De Toro Carmena M, Guill\u00e9n-Ponce C, et al. 2026 Systemic Inflammation Response Index integrates host inflammation to predict outcomes and treatment benefit in metastatic pancreatic cancer: a study by the PANTHEIA-SEOM Research Group. Pancreatology","DOI":"10.1016\/j.pan.2026.08.008"},{"key":"4554_CR11","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.","journal-title":"BMJ"},{"issue":"9596","key":"4554_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"16","key":"4554_CR13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180\u20134.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"4554_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4554_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1\u201367.","journal-title":"J Stat Softw"},{"issue":"29","key":"4554_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","volume":"35","author":"EW Steyerberg","year":"2014","unstructured":"Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925\u201331.","journal-title":"Eur Heart J"},{"issue":"17-18","key":"4554_CR17","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/(SICI)1097-0258(19990915\/30)18:17\/18<2529::AID-SIM274>3.0.CO;2-5","volume":"18","author":"E Graf","year":"1999","unstructured":"Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med. 1999;18(17\u201318):2529\u201345.","journal-title":"Stat Med"},{"key":"4554_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis","author":"FE Harrell Jr.","year":"2015","unstructured":"Harrell FE Jr. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed. Springer; 2015.","edition":"2nd ed"},{"key":"4554_CR19","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2023."},{"issue":"2","key":"4554_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.sla.0000133125.85489.07","volume":"240","author":"MF Brennan","year":"2004","unstructured":"Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240(2):293\u20138.","journal-title":"Ann Surg"},{"issue":"30","key":"4554_CR21","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1200\/JCO.2005.01.8101","volume":"23","author":"CR Ferrone","year":"2005","unstructured":"Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL. Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol. 2005;23(30):7529\u201335.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4554_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ejso.2019.12.023","volume":"46","author":"S van Roessel","year":"2020","unstructured":"van Roessel S, Strijker M, Steyerberg EW, Groen JV, Mieog JS, Groot VP, et al. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Eur J Surg Oncol. 2020;46(5):796\u2013803.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"4554_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.surg.2022.05.024","volume":"172","author":"G Qiao","year":"2022","unstructured":"Qiao G, Ilagan CH, Fernandez-Del Castillo C, Ferrone CR, Janseen QP, Balachandran VP, et al. Development and validation of the Massachusetts General Hospital\/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy. Surgery. 2022;172(4):1228\u201335.","journal-title":"Surgery"},{"issue":"19","key":"4554_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"1","key":"4554_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/sim.2331","volume":"25","author":"P Royston","year":"2006","unstructured":"Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25(1):127\u201341.","journal-title":"Stat Med"},{"issue":"2","key":"4554_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/djaa073","volume":"113","author":"T Michelakos","year":"2021","unstructured":"Michelakos T, Cai L, Villani V, Sabbatino F, Kontos F, Fern\u00e1ndez-Del Castillo C, et al. Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. J Natl Cancer Inst. 2021;113(2):182\u201391.","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"4554_CR27","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","volume":"391","author":"JD Groarke","year":"2024","unstructured":"Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, et al. Ponsegromab for the Treatment of Cancer Cachexia. N Engl J Med. 2024;391(24):2291\u2013303.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04554-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:01:06Z","timestamp":1788415266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04554-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":27,"alternative-id":["4554"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04554-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V. Pacheco-Barcia has received research support from Nutricia, Pfizer, Servier and Leo Pharma for PANTHEIA-SEOM research; speaker honoraria from Pierre Fabre, Nutricia, Servier, Pfizer, AstraZeneca, Leo Pharma; consultancy or advisory board from Advanced Accelerator Applications, a Novartis company, Pfizer, Nutricia, Servier; travel support from Amgen, Servier, Pfizer, Nutricia, Merck. No other disclosures were reported.A. Mari\u00f1o-Mendez reported receiving speaker honoraria from AstraZeneca and Recordati; educational support from Merck; travel support from Bristol Myers Squibb, Leo Pharma, Merck, MSD, Nutricia, Pierre Fabre, and Pfizer. No other disclosures were reported.P. Cerd\u00e0 has received speaker honoraria from Eisai, Roche, AstraZeneca, BMS, and MSD; consultancy or advisory board from BMS and AstraZeneca; travel support from Roche, AstraZeneca, MSD, Eisai, Servier, Lilly, and Nutricia. No other disclosures were reported.A. Lamarca declares Travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan, Delcath Advanz Pharma, and Roche; Speaker honoraria from Merck, Pfizer, Ipsen, Incyte, AAA\/Novartis, QED, Servier, AstraZeneca, EISAI, Roche, Advanz Pharma, Jazz Therapeutics, and MSD; Advisory and consultancy honoraria from EISAI, Nutricia, Ipsen, QED, Roche, Servier, Boston Scientific, Albireo Pharma, AstraZeneca, Boehringer Ingelheim, GENFIT, TransThera Biosciences, Taiho, MSD, JAZZ Therapeutics, and Viatris; Principal Investigator-associated Institutional Funding from QED, Merck, Boehringer Ingelheim, Servier, Astra Zeneca, GenFit, Panbela Therapeutics, Novocure GmbH, Camurus AB, Albireo Pharma, Taiho, TransThera, Jazz Therapeutics, Roche, Novartis, Crinetics Pharmaceuticals, MSD, AbbVie, Revolution Medicines, and Incyte; Member of the Knowledge Network and NETConnect Initiatives funded by Ipsen.E. Brozos-Vazquez declares fee\u00b4s speaking from LEO Pharma, Rovi, Roche, Kyowa Kirin, Merck, Bayer, Pierre Fabre, Sanofi, Amgen; and Advisory honoraria from Servier, Pfizer, and Bayer.J. Adeva reported financial interests from Incyte, Advisory Board, Personal; Servier, Advisory Board, Personal; MSD, Advisory Board, Personal; Taiho Oncology, Advisory Board, Personal; AstraZeneca, Advisory Board, Personal; Incyte, Invited Speaker, Personal; Servier, Invited Speaker, Personal; MSD, Invited Speaker, Personal; AstraZeneca, Invited Speaker, Personal; Taiho Oncology, Invited Speaker, Personal; and Non-Financial Interests from Servier, Principal Investigator Taiho Oncology, Principal Investigator; AstraZeneca, Principal Investigator.A. L\u00f3pez-Alfonso reported financial interests speaker honoraria from AstraZeneca, Servier, AstraZeneca.S. Soriano reported receiving educational support from Merck, Novartis; travel support from Merck, MSD, Ipsen, Novartis, Takeda.J. Soto Alsar reported receiving research support from Pierre Fabre and Amgen; and speaker or consultant honoraria from LEO Pharma, MSD, BMS, Takeda, Roche, Merck, Pfizer, Recordati, AstraZeneca, Nestl\u00e9, Abbott, Techdow.A. Mu\u00f1oz reported consultant or advisory role for GSK, Pfizer, BMS-Celgene, Sanofi, Astra-Zeneca, MSD, Lilly, Servier, Roche, Taiho, Leo Pharma, Regeneron, Jazz Pharmaceuticals. Research funding from Leo Pharma. Speakers\u2019 bureau: Rovi, Menarini, Stada, Medscape, Incyte, Taiho. Patents, Royalties, Other Intellectual Property: Risk assessment model in venous thromboembolism in cancer patients (genomic risk score). Liquid biopsy developed with Laser technology.P. Jimenez-Fonseca reported receiving research support from Astellas, AstraZeneca, BMS, and MSD; and speaker or consultant honoraria from Amgen, Astellas, AstraZeneca, BeiGene, BMS, Esteve, Leo Pharma, MSD, Novartis, Nutricia, Pfizer, Pierre Fabre, Rovi, Servier, Takeda, and Viatris.A. Carmona-Bayonas reported receiving research support from Astellas, AstraZeneca, BMS, and MSD; speaker honoraria from Novartis and Astellas; consultant honoraria from Astellas; and travel support from Amgen, Astellas, and Servier.The remaining authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}